Seelos Therapeutics' SLS-002 Shows Clinically Meaningful Efficacy As Anti-Depressive, Anti-Suicidal Therapeutic After Single Dose

Seelos Therapeutics Inc SEEL has announced data from Part 1, the open-label cohort, of its Proof-of-Concept study of SLS-002 for acute suicidal ideation and behavior in patients with Major Depressive Disorder.
On depression scale, 76.5% response rate on Day 1 (n=17), 92.9% response rate on Day 16 (n=14) and 100% response rate on Day 29 (n=13) was observed.
35.3% remission rate on Day 1, 78.6 % remission rate on Day 16, and 76.9% remission rate on day 29.
94% of subjects had more than 14 points within-patient change on the suicidality tracking scale from their baseline and one subject = 4 points within-patient change on Day 1.
SLS-002 was well tolerated, with 47% of subjects having at least one treatment-emergent adverse event.
No serious adverse events were observed, and all adverse events were mild or moderate, mostly transient in nature, and with no new or unique safety signals identified.
Price Action: SEEL shares are trading 17% lower at $4.31 during the premarket session on the last check Monday.